ITeos Therapeutics Has Dosed First Patient In GALAXIES Lung-301 Phase 3 Trial Of Belrestotug+Dostarlimab Vs. Placebo+Pembrolizumab For First-line Advanced, Unresectable, Or Metastatic PD-L1 High Non-Small Cell Lung Cancer
ITeos Therapeutics Has Dosed First Patient In GALAXIES Lung-301 Phase 3 Trial Of Belrestotug+Dostarlimab Vs. Placebo+Pembrolizumab For First-line Advanced, Unresectable, Or Metastatic PD-L1 High Non-Small Cell Lung Cancer
This event has triggered $35 million in development milestone payments from GSK, its partner for belrestotug.
這一事件已經觸發了全球貨幣3500萬的開發階段支付，這是其合作伙伴GSk爲belrestotug所支付的。
iTeos and GSK entered into an exclusive development and commercialization collaboration in June 2021 for belrestotug, an anti-TIGIT monoclonal antibody, enabling novel next-generation immuno-oncology combinations. Per the agreement, iTeos received a $625 million upfront payment from GSK with development and regulatory milestones up to $550 million and commercial milestones up to $900 million. In addition to the milestones, GSK and iTeos will jointly commercialize and equally split profits in the US. Outside the US, GSK will receive an exclusive license for commercialization and iTeos will receive tiered royalty payments. Within the collaboration, GSK and iTeos share responsibility and costs for the global development of belrestotug.
iTeos和GSk於2021年6月簽署了一項獨家開發和商業化合作協議，旨在合作開發抗TIGIt單克隆抗體belrestotug，以實現創新的下一代免疫治療組合。根據協議，iTeos從GSk獲得了62500萬美元的預付款，並獲得了高達55000萬美元的開發和監管里程碑以及高達90000萬美元的商業里程碑。除了里程碑外，GSk和iTeos在美國共同商業化並平分利潤。在美國以外地區，GSk將獲得商業化的獨家許可，iTeos將獲得分層版稅支付。在合作中，GSk和iTeos共同承擔全球貨幣的開發責任和成本。
譯文內容由第三人軟體翻譯。